Pluristyx Expands Patent Portfolio for Universal Cell Therapy

New U.S. patent covers iACT Stealth™ technology for autoimmune disease treatments

Apr. 7, 2026 at 11:36am

Got story updates? Submit your updates here. ›

A bold, abstract painting featuring sweeping geometric arcs, concentric circles, and precise botanical spirals in soft, earthy tones of green, blue, and ochre, conceptually representing the complex scientific forces and intelligent design behind Pluristyx's iACT Stealth technology for autoimmune cell therapies.Pluristyx's innovative 'cell cloaking' technology represents a new frontier in regenerative medicine, empowering engineered cells to precisely retrain the immune system and induce long-term remission of autoimmune diseases.Seattle Today

Pluristyx, a leader in advanced induced pluripotent stem cell (iPSC)-based solutions, has announced the expansion of its intellectual property portfolio with a new U.S. patent allowance. The patent covers the use of Pluristyx's exclusive iACT Stealth™ technology, which allows for the 'cloaking' of cells to train a patient's immune system to stop attacking itself in autoimmune diseases, without the need for broad immune suppression.

Why it matters

This patent marks a significant shift in the use of cell therapy beyond oncology, enabling the development of 'tolerogenic' cell therapies that can specifically retrain the immune system to stop attacking itself in autoimmune diseases. Unlike traditional methods that broadly suppress the immune system, leaving patients vulnerable, this technology allows engineered cells to persist in the body and precisely target the root cause of autoimmune conditions.

The details

The newly allowed patent claims are specifically drawn to the use of iACT Stealth™ in the treatment of autoimmune diseases. Pluristyx can combine a genetic engineering package integrating iACT Stealth with self-antigen technology, and 'train' a patient's own immune system to mount a precise, desired immune response to a self-antigen without dangerous 'off-target' effects or using traditional debilitating systemic immune suppression. This innovative approach represents a new frontier in 'living medicine,' where engineered iPSC-derived cells act as a localized, intelligent platform for long-term autoimmune remission.

  • Pluristyx announced the patent allowance on April 7, 2026.

The players

Pluristyx

A leader in advanced induced pluripotent stem cell (iPSC)-based solutions, providing a comprehensive platform designed to accelerate therapeutic development with unmatched speed, safety, and scalability.

Kaye Reiter, PhD, JD

Pluristyx Chief Legal Officer, who stated that this patent addition furthers the company's commitment to advancing regenerative, living-medicine therapies in the autoimmune field.

Got photos? Submit your photos here. ›

What they’re saying

“This addition to our patent portfolio furthers our commitment to advancing regenerative, living-medicine therapies, now in the autoimmune field. We continue to expand our exclusive intellectual property portfolio of combined iPSC, FailSafe, and iACT Stealth technologies that are setting the standard for functionality, safety, and scalability.”

— Kaye Reiter, PhD, JD, Pluristyx Chief Legal Officer

What’s next

Pluristyx's full suite of technologies, including iACT Stealth, FailSafe, and proprietary mRNA-based iPSC reprogramming technology, is available for immediate adoption through a streamlined research evaluation and commercial licensing model, providing partners with a powerful, clinical-grade foundation to bring next-generation living medicines to market.

The takeaway

This patent represents a significant breakthrough in the use of cell therapy for autoimmune diseases, enabling the development of targeted, 'tolerogenic' cell therapies that can retrain the immune system without broad immunosuppression. Pluristyx's innovative approach to combining iPSC, safety, and immune-evasion technologies is setting new standards for the future of regenerative medicine.